Crispr Therapeutics shares tumble after significant earnings miss
BANNOCKBURN, Ill. - Option Care Health, Inc. (NASDAQ:OPCH), the nation’s largest independent provider of home and alternate site infusion services, reported second quarter earnings that exceeded analyst expectations, with revenue climbing 15.4% YoY to $1.42 billion, above the consensus estimate of $1.35 billion.
The company posted adjusted earnings per share of $0.41, beating analyst estimates of $0.38. Revenue growth was driven by strong performance across its infusion services, with total revenue reaching $1.42 billion compared to $1.23 billion in the same quarter last year. Gross profit increased 7.9% to $269 million, though gross margin contracted to 19% from 20.3% in the year-ago period.
"I am proud of the second quarter performance and the Option Care Health team’s ability to show resilience in a dynamic marketplace," said John C. Rademacher, Chief Executive Officer. "We continue to execute on opportunities to provide strong clinical outcomes while helping reduce the total cost of care."
The company’s adjusted EBITDA rose 5.2% to $114 million compared to $108.4 million in the second quarter of 2024. Cash flow from operations was $90.3 million, down from $195.7 million in the same period last year. The company also repurchased approximately $50 million of stock during the quarter.
Looking ahead, Option Care Health updated its full-year 2025 guidance, now expecting revenue between $5.5 billion and $5.65 billion, in line with the analyst consensus of $5.54 billion. The company forecasts adjusted EPS of $1.65 to $1.72, compared to the consensus estimate of $1.68, and adjusted EBITDA of $465 million to $475 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.